NCT06252948 (Microbiome) is a clinical trial of Non-interventional study (observational) in Plasma Cell Disorders, sponsored by Mayo Clinic.

Who is sponsoring NCT06252948?

NCT06252948 is sponsored by Mayo Clinic.

What drugs are being tested in NCT06252948?

Interventions in NCT06252948: Non-interventional study (observational).

What condition does NCT06252948 study?

NCT06252948 studies Plasma Cell Disorders.

Is NCT06252948 still recruiting?

NCT06252948 is currently recruiting now. Last updated 23 February 2026.

Last reviewed 2026-02-23 · How we verify

NCT06252948: Microbiome

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders

Recruiting now Last updated 23 February 2026

What this trial tests

trial testing Non-interventional study (observational) in Plasma Cell Disorders in 240 participants. Currently enrolling.

Timeline

29 December 2021

Primary endpoint
1 December 2028

29 December 2028

Quick facts

Lead sponsor	Mayo Clinic
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	240
Start date	29 December 2021
Primary completion	1 December 2028
Estimated completion	29 December 2028
Sites	1 location across United States

Drugs / interventions tested

Non-interventional study (observational)

Conditions studied

Plasma Cell Disorders — all drugs for Plasma Cell Disorders →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Plasma Cell Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Plasma Cell Disorders

Currently open trials in the same condition.

NCT07115667 — Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infilt · Phase 2 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06252948 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 23 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06252948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing